Natasja Viller has 13 years of drug development experience with a focus on advancing therapies from pre-clinical to clinical proof-of-concept. She excels in strategic planning and bridging drug discovery with translational studies, and her expertise spans due diligence, defining development roadmaps, and building high-performing teams. Natasja’s medical affairs experience provides a unique perspective on drug commercialization, enabling her to align scientific and clinical strategies with market needs.

Before joining Kivu Bioscience, she held leadership roles at Fable Therapeutics, Triphase Accelerator and Trillium Therapeutics, advancing immuno-oncology assets, ADCs, and novel AI platforms. Natasja obtained her Ph.D. in Immunology from the University of Copenhagen, followed by Postdoctoral training at Novo Nordisk in Denmark.